Collaboration › Details

JnJ–Celsius Therapeutics: biomarker discovery, 201907– collab to identify biomarkers for ulcerative colitis with Janssen Biotech Inc

 

Period Period 2019-07-09
Organisations Partner, 1st Janssen Biotech Inc. (JBI)
  Group Johnson & Johnson (JnJ) (Group)
  Partner, 2nd Celsius Therapeutics Inc.
Products Product biomarker discovery services
  Product 2 guselkumab (CNTO1959)
     

Celsius Therapeutics Inc.. (7/9/19). "Press Release: Celsius Therapeutics Signs Collaboration Agreement with Janssen to Identify Response Biomarkers for Ulcerative Colitis". Cambridge, MA.

Celsius to Apply its Single-Cell Genomics and Machine Learning Platform at Unprecedented Scale in Large Phase 2 Clinical Study


Celsius Therapeutics, a company focused on the discovery and development of precision therapeutics for patients with autoimmune diseases and cancer, today announced a collaboration with Janssen Biotech, Inc. Under the terms of the agreement, Celsius will apply its proprietary single-cell genomics and machine learning platform to identify predictive biomarkers of response from Janssen’s VEGA study, a Phase 2a clinical trial evaluating the efficacy and safety of combination therapy with guselkumab and golimumab in patients with ulcerative colitis.

“We are very pleased to be collaborating with Janssen, a company with a long-standing commitment to improving the lives of patients with inflammatory bowel disease,” said Tariq Kassum, M.D., chief executive officer of Celsius. “As our first industry partnership, it serves as a model for how we can apply our integrated platform to identify the specific patients who will benefit from existing and investigational therapies, while simultaneously gathering data that will fuel Celsius’ novel target and drug discovery engine.”

Celsius will receive undisclosed payments along with potential milestones based on the use of biomarkers identified in the collaboration. Celsius retains the ability to integrate the clinical and sample-level data generated from the study into its growing database of patient and single-cell genomic information, and will further interrogate the data for its own target and drug discovery efforts.

“Celsius has built an industrialized platform at the scale necessary to consistently process intact patient samples and to rapidly integrate and interrogate the large datasets being generated across this global multicenter study,” said Christoph Lengauer, Ph.D., co-founder and chief scientific officer of Celsius. “The longitudinal patient datasets and sample-level information generated through this large study will enable Celsius and Janssen to extract deep molecular and cellular insights, which we hope will ultimately lead to better treatments for patients.”


About Celsius Therapeutics

Celsius Therapeutics is charting a new course of target and drug discovery by applying a systematic approach to single-cell sequencing of patient tissue, combining massive datasets, complex algorithms, and machine learning to discover first-in-class precision therapies with a transformative impact on the lives of patients with autoimmune diseases and cancer. Celsius was launched in 2018, is backed by Third Rock Ventures and GV (formerly Google Ventures), and is based in Cambridge, Mass. For more information, please visit www.celsiustx.com.


Contact

Katie Engleman
1AB
katie@1abmedia.com

CELSIUS THERAPEUTICS
399 Binney Street
Cambridge, MA 02139
857-776-7400
info@celsiustx.com

   
Record changed: 2019-07-19

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x91px

More documents for Johnson & Johnson (JnJ) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x113px




» top